| JARDIN, Fabrice |
LOTIS 5, NCT04384484 / 2020-000241-14: Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma |
|
|
| Active, not recruiting | 3 | 440 | Europe, Canada, Japan, US, RoW | Loncastuximab Tesirine, Zynlonta, ADCT-402, Rituximab, Gemcitabine, Oxaliplatin | ADC Therapeutics S.A., ADC Therapeutics SA | Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | 06/25 | 06/28 | | |
|
|
|
SYMPHONY-1, NCT04224493 / 2019-003333-42: A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma. |
|
|
| Recruiting | 3 | 612 | Europe, Canada, US, RoW | Tazemetostat, EPZ-6438, IPN60200, Placebo oral tablet, Lenalidomide, Rituximab | Epizyme, Inc. | Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma | 03/26 | 03/29 | | |
|
|
|
|
|
|
|
GLOASIS, NCT06558604: A Phase II Study Evaluating Glofitamab in Combination With Venetoclax Plus Zanubrutinib or Venetoclax Alone in Subjects With Untreated or Relapsed/Refractory High-risk Mantle-cell Lymphoma |
|
|
| Recruiting | 2 | 100 | Europe | Obinutuzumab, Glofitamab, Venetoclax Oral Product, Zanubrutinib Oral Capsule | The Lymphoma Academic Research Organisation, BeiGene, Hoffmann-La Roche | Lymphoma, Mantle-Cell | 05/28 | 03/32 | | |
| Recruiting | N/A | 5000 | Europe | | The Lymphoma Academic Research Organisation, Gilead Sciences, Novartis, Bristol-Myers Squibb | Hematopathology Eligible or CAR-t Cell Treatment | 12/38 | 12/38 | | |
| Tempescul, Adrian |
LOTIS 5, NCT04384484 / 2020-000241-14: Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma |
|
|
| Active, not recruiting | 3 | 440 | Europe, Canada, Japan, US, RoW | Loncastuximab Tesirine, Zynlonta, ADCT-402, Rituximab, Gemcitabine, Oxaliplatin | ADC Therapeutics S.A., ADC Therapeutics SA | Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | 06/25 | 06/28 | | |
|
|
|
SYMPHONY-1, NCT04224493 / 2019-003333-42: A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma. |
|
|
| Recruiting | 3 | 612 | Europe, Canada, US, RoW | Tazemetostat, EPZ-6438, IPN60200, Placebo oral tablet, Lenalidomide, Rituximab | Epizyme, Inc. | Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma | 03/26 | 03/29 | | |
|
|
|
|
|
|
|
| Recruiting | N/A | 5000 | Europe | | The Lymphoma Academic Research Organisation, Gilead Sciences, Novartis, Bristol-Myers Squibb | Hematopathology Eligible or CAR-t Cell Treatment | 12/38 | 12/38 | | |
| Gastinne, Thomas |
| Recruiting | 3 | 225 | Europe, Canada, Japan, US, RoW | Olorofim, Olorofim (F901318), AmBisome®, AmBisome® (liposomal amphotericin B) | F2G Biotech GmbH, Iqvia Pty Ltd, Shionogi | Invasive Aspergillosis | 09/25 | 11/26 | | |
| Active, not recruiting | 3 | 500 | Europe, Canada, Japan, US, RoW | Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib, Imbruvica, Acalabrutinib, Calquence, Zanubrutinib, Brukinsa | Loxo Oncology, Inc., Eli Lilly and Company | Lymphoma, Mantle-Cell | 12/25 | 07/26 | | |
| Active, not recruiting | 3 | 240 | Europe, Canada, US, RoW | Brentuximab vedotin, Rituximab, Lenalidomide, Placebo | Seagen Inc. | Diffuse Large B-cell Lymphoma | 05/25 | 04/27 | | |
|
SYMPHONY-1, NCT04224493 / 2019-003333-42: A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma. |
|
|
| Recruiting | 3 | 612 | Europe, Canada, US, RoW | Tazemetostat, EPZ-6438, IPN60200, Placebo oral tablet, Lenalidomide, Rituximab | Epizyme, Inc. | Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma | 03/26 | 03/29 | | |
|
|
|
|
|
|
|
| Active, not recruiting | 2 | 168 | Europe, RoW | MB-CART2019.1, R-GemOx or BR plus polatuzumab vedotin, Rituximab, Gemcitabine, Oxaliplatin, Polatuzumab vedotin, Bendamustine, Rituximab | Miltenyi Biomedicine GmbH, ICON plc | Diffuse Large B-cell Lymphoma | 12/24 | 07/29 | | |
| Recruiting | 2 | 56 | Europe | Lacutamab, Gemcitabine, Oxaliplatine | The Lymphoma Academic Research Organisation, Innate Pharma | Peripheral T Cell Lymphoma, Relapse/Recurrence | 01/25 | 01/27 | | |
|
| Recruiting | 2 | 180 | Europe, Japan, US, RoW | Epcoritamab, GEN3013, DuoBody®-CD3×CD20, EPKINLY™, Lenalidomide, Revlimid® | Genmab, AbbVie | Diffuse Large B-Cell Lymphoma | 01/26 | 03/27 | | |
| Recruiting | 1/2 | 210 | Europe, US, RoW | CPI-0209 | Constellation Pharmaceuticals | Advanced Solid Tumor, Diffuse Large B Cell Lymphoma, Lymphoma, T-Cell, Mesothelioma, Malignant, Prostatic Neoplasms, Castration-Resistant, Endometrial Cancer, Ovarian Clear Cell Carcinoma | 12/25 | 03/26 | | |
| Recruiting | N/A | 5000 | Europe | | The Lymphoma Academic Research Organisation, Gilead Sciences, Novartis, Bristol-Myers Squibb | Hematopathology Eligible or CAR-t Cell Treatment | 12/38 | 12/38 | | |
| Jiang, Bo |
NCT04624854: Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT-MVD) |
|
|
| Active, not recruiting | 4 | 8250 | RoW | Clopidogrel and Aspirin dual-antiplatelet therapy, Aspirin monotherapy | Harbin Medical University, Chinese Society of Cardiology, Lepu Medical Technology (Beijing) Co., Ltd. | Coronary Artery Disease, Myocardial Ischemia, Acute Coronary Syndrome, Heart Diseases, Syndrome Heart Disease, Cardiovascular Diseases, Arteriosclerosis, Arterial Occlusive Diseases, Coronary Disease, Vascular Diseases | 04/25 | 04/25 | | |
NCT05181137 / 2021-001940-86: A Phase 3 Study to Investigate the Efficacy and Safety of SHR0302 With Moderately to Severely Active Ulcerative Colitis |
|
|
| Recruiting | 3 | 368 | Europe, US, RoW | SHR0302, Placebo | Reistone Biopharma Company Limited, Reistone Biopharma Company Limited | Ulcerative Colitis | 10/24 | 03/25 | | |
NCT06206174: TGRX-814 Chinese Phase I/II in Patients With Hematological Malignancies |
|
|
| Recruiting | 1/2 | 30 | RoW | TGRX-814, TGRX-814 monotherapy | Shenzhen TargetRx, Inc., Institute of Hematology & Blood Diseases Hospital, China | Hematologic Malignancy, Non Hodgkin Lymphoma, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Adult, Myelodysplastic Syndromes | 02/25 | 02/29 | | |
NCT05380427: A Phase I Clinical Trial Evaluating the Safety, Tolerability, and Pharmacokinetics of CU-40101 Liniment in Single and Multiple Doses in Adult Male Androgenic Alopecia Subjects |
|
|
| Completed | 1 | 80 | RoW | CU-40101 | Cutia Therapeutics（Wuxi）Co.,Ltd | AGA | 11/23 | 02/24 | | |
HRS-7249-101, NCT06541457: A Study on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-7249 Injection in Healthy Subjects |
|
|
| Recruiting | 1 | 48 | RoW | HRS-7249 injection, Placebo | Fujian Shengdi Pharmaceutical Co., Ltd. | Hyperlipidemia | 05/25 | 05/25 | | |
NCT04872491: A Study of Vedolizumab in Adults in Real-World Practice |
|
|
| Completed | N/A | 500 | RoW | | Takeda | Colitis, Ulcerative, Crohn Disease | 07/24 | 07/24 | | |
| Yao, Ke |
NCT06183814: A Study of EXG102-031 in Participants With wAMD |
|
|
| Recruiting | 1/2 | 42 | RoW | EXG102-031 | Hangzhou Jiayin Biotech Ltd | Neovascular Age-related Macular Degeneration | 12/25 | 12/25 | | |
| Yuan, Ying |
| Recruiting | 3 | 918 | Europe, Canada, Japan, RoW | Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil | Jazz Pharmaceuticals, BeiGene, Ltd. | Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma | 05/25 | 05/26 | | |
| Recruiting | 3 | 400 | Europe, Canada, Japan, US, RoW | tucatinib, TUKYSA, ONT-380, ARRY-380, PF-07265792, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil | Seagen Inc., Merck Sharp & Dohme LLC | Colorectal Neoplasms | 08/25 | 04/28 | | |
AZUR-2, NCT05855200: Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer |
|
|
| Recruiting | 3 | 711 | Europe, Canada, Japan, US, RoW | Dostarlimab, CAPEOX, FOLFOX | GlaxoSmithKline | Colonic Neoplasms, Neoplasms, Colon | 12/28 | 12/30 | | |
BEVTOR, NCT04527068: QL1101 in Combination With JS001 in Patients With pMMR/MSS Refractory Metastatic Colorectal Cancer |
|
|
| Not yet recruiting | 2 | 50 | RoW | Bevacizumab, QL1101, Tripleitriumab, JS001 | Second Affiliated Hospital, School of Medicine, Zhejiang University, Qilu Pharmaceutical Co., Ltd., Shanghai Junshi Bioscience Co., Ltd. | Refractory Metastatic Colorectal Cancer, pMMR, MSS | 09/21 | 02/22 | | |
TranStar102, NCT04495296: A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors |
|
|
| Recruiting | 1/2 | 320 | RoW | TST001, Oxaliplatin, Capecitabine, Paclitaxel, Gemcitabine, Cisplatin, Nivolumab | Suzhou Transcenta Therapeutics Co., Ltd., Bristol-Myers Squibb | Advanced Cancer | 02/25 | 05/25 | | |
NCT06214143: A Clinical Study of T3011 in Combination With PD-1/PD-L1 Inhibitors in Subjects With Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 68 | RoW | T3011 high dose, T3011 middle dose, T3011 low dose | Shanghai Pharmaceuticals Holding Co., Ltd | Advanced Solid Tumors | 12/25 | 05/26 | | |
NCT05260385: To Evaluate KC1036 in the Patients with Advanced Digestive System Tumors |
|
|
| Recruiting | 1/2 | 133 | RoW | KC1036 | Beijing Konruns Pharmaceutical Co., Ltd. | Digestive System Tumors | 10/25 | 12/25 | | |
NCT05338957: A Study of MRG002 in the Treatment of Patients With HER2-expressed Advanced Malignant Solid Tumors. |
|
|
| Recruiting | 1/2 | 30 | RoW | MRG002+HX008 | Shanghai Miracogen Inc. | Advanced Malignant Solid Tumors | 06/24 | 12/24 | | |
NCT06500676: A Study of GFH375 in Patients with Advanced Solid Tumors with KRAS G12D Mutations |
|
|
| Recruiting | 1/2 | 290 | RoW | GFH375 | Genfleet Therapeutics (Shanghai) Inc. | KRAS G12D Mutations, Advanced Solid Tumors | 07/28 | 12/28 | | |
| Recruiting | 1 | 60 | RoW | SG1906 | Hangzhou Sumgen Biotech Co., Ltd. | Locally Advanced Unresectable or Metastatic Solid Tumors | 02/25 | 08/25 | | |
NCT05501912: A Study of ABM-1310 in Patients With BRAF V600-Mutant Advanced Solid Tumors |
|
|
| Terminated | 1 | 20 | RoW | ABM-1310 | ABM Therapeutics Shanghai Company Limited | Advanced Solid Tumor, BRAF V600 Mutation | 06/24 | 06/24 | | |
NCT06043466: A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors |
|
|
| Recruiting | 1 | 30 | RoW | CEA-targeted CAR-T cells | Chongqing Precision Biotech Co., Ltd, Zhejiang University | Colorectal Cancer, Esophagus Cancer, Gastric Cancer, Pancreas Cancer, Non-small Cell Lung Cancer, Breast Cancer, Bile Duct Cancer | 12/26 | 12/27 | | |
NCT06101030: Comparing Use of Incentive Spirometry with and Without Reminder |
|
|
| Recruiting | N/A | 500 | US | Signal On | Tidal Medical Technologies | Post Operative | 03/25 | 07/25 | | |
SUMMIT, NCT03433274: Clinical Trial to Evaluate the Safety and Effectiveness of Using the Tendyne Transcatheter Mitral Valve System for the Treatment of Symptomatic Mitral Regurgitation |
|
|
| Recruiting | N/A | 958 | Canada, US | Tendyne Mitral Valve System, MitraClip System | Abbott Medical Devices | Mitral Regurgitation, Mitral Insufficiency, Mitral Valve Insufficiency, Cardiovascular Diseases, Valve Disease, Heart, Heart Valve Diseases, Functional Mitral Regurgitation, Degenerative Mitral Valve Disease | 05/24 | 06/28 | | |
ICE-AFIB, NCT03732794: AtriCure CryoICE Lesions for Persistent and Long-standing Persistent Atrial Fibrillation Treatment |
|
|
| Active, not recruiting | N/A | 150 | US | AtriCure CryoICE & AtriClip LAA Exclusion | AtriCure, Inc. | Atrial Fibrillation (AF), Persistent Atrial Fibrillation, Longstanding Persistent Atrial Fibrillation | 06/24 | 06/26 | | |
| Drenou, Bernard |
SYMPHONY-1, NCT04224493 / 2019-003333-42: A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma. |
|
|
| Recruiting | 3 | 612 | Europe, Canada, US, RoW | Tazemetostat, EPZ-6438, IPN60200, Placebo oral tablet, Lenalidomide, Rituximab | Epizyme, Inc. | Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma | 03/26 | 03/29 | | |
|
|
|
|
|
|
|
| Active, not recruiting | 2 | 82 | Europe, US, RoW | brentuximab vedotin, ADCETRIS, cyclophosphamide, doxorubicin, prednisone | Seagen Inc. | Peripheral T-cell Lymphoma | 05/24 | 12/25 | | |
| Active, not recruiting | 2 | 141 | Europe | Valemetostat tosylate, DS-3201b | The Lymphoma Academic Research Organisation, Daiichi Sankyo | Lymphoma, B-Cell | 10/24 | 10/24 | | |
NCT06588478: A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma |
|
|
| Recruiting | 2 | 249 | Europe, Canada, US, RoW | Pirtobrutinib | Loxo Oncology, Inc., Eli Lilly and Company | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 06/28 | 12/28 | | |
FOLLOW, NCT05590702: French Observational Study of Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in Real-World Settings |
|
|
| Recruiting | N/A | 1000 | Europe | First line therapy | French Innovative Leukemia Organisation, AbbVie, AstraZeneca, BeiGene, Janssen-Cilag Ltd. | CLL/SLL | 11/25 | 12/32 | | |
| Qian, Wenbin |
| Recruiting | 3 | 240 | RoW | Equecabtagene Autoleucel Injection, FUCASO, Daratumumab, Pomalidomide, Bortezomib, Dexamethasone | Nanjing IASO Biotechnology Co., Ltd. | Multiple Myeloma | 08/27 | 12/30 | | |
NCT06363994: A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL |
|
|
| Recruiting | 3 | 476 | RoW | Orelabrutinib, Bendamustine Injection, Rituximab, Orelabrutinib Placebo | InnoCare Pharma Inc. | Mantle Cell Lymphoma | 06/31 | 06/32 | | |
NCT06508983: A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients |
|
|
| Recruiting | 3 | 360 | RoW | SG301 Injection, SG301 placebo, pomalidomide, dexamethasone | Hangzhou Sumgen Biotech Co., Ltd. | Relapsed/Refractory Multiple Myeloma | 03/27 | 03/28 | | |
SYMPHONY-1, NCT04224493 / 2019-003333-42: A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma. |
|
|
| Recruiting | 3 | 612 | Europe, Canada, US, RoW | Tazemetostat, EPZ-6438, IPN60200, Placebo oral tablet, Lenalidomide, Rituximab | Epizyme, Inc. | Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma | 03/26 | 03/29 | | |
|
|
|
|
|
|
|
NCT03934567: A Multi-Center Phase 2 Study to Evaluate Efficacy and Safety of Oral Abexinostat as Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma |
|
|
| Recruiting | 2 | 96 | RoW | Abexinostat | Xynomic Pharmaceuticals, Inc. | Lymphoma, Follicular | 02/24 | 09/24 | | |
NCT04674514: APG-2575 Monotherapy or in Combination With Lenalidomide/DXMS in Subjects With Relapsed or Refractory Multiple Myeloma |
|
|
| Recruiting | 1/2 | 48 | RoW | APG-2575, Rd, Lenalidomide +Dexamethasone | Ascentage Pharma Group Inc. | Multiple Myeloma | 01/24 | 05/24 | | |
NCT04494503: Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL |
|
|
| Recruiting | 1/2 | 123 | RoW | APG-2575, Rituximab, Ibrutinib | Ascentage Pharma Group Inc. | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 12/24 | 12/25 | | |
NCT04861779: A Study of HSK29116 in Adults With Relapsed/Refractory B-cell Malignancies |
|
|
| Recruiting | 1 | 156 | RoW | HSK29116 | Haisco Pharmaceutical Group Co., Ltd. | Relapsed/Refractory B-Cell Malignancies | 08/23 | 10/23 | | |
NCT04706936: Novel BCMA-targeted CAR-T Cell Therapy for Multiple Myeloma |
|
|
| Recruiting | 1 | 25 | RoW | anti-BCMA CAR-T, CBG-002 CAR-T, Cyclophosphamid, Fludarabine | Second Affiliated Hospital, School of Medicine, Zhejiang University, Carbiogene Therapeutics Co. Ltd. | Relapsed or Refractory Multiple Myeloma | 10/23 | 04/24 | | |
NCT04795128: A Study Evaluating the Safety, Tolerability and Preliminary Efficacy of IBI322 in Subjects With Hematologic Malignancy |
|
|
| Completed | 1 | 70 | RoW | IBI322 | Innovent Biologics (Suzhou) Co. Ltd. | Hematologic Malignancy | 08/23 | 08/23 | | |
NCT06142175: Relmacabtagene Autoleucel in Patients With LBCL |
|
|
| Recruiting | N/A | 200 | RoW | Relmacabtagene Autoleucel, JWCAR029 | Shanghai Ming Ju Biotechnology Co., Ltd. | Large B-cell Lymphoma | 12/24 | 12/24 | | |
NCT04837222: A Study of Brentuximab Vedotin in Adults With CD30-positive Lymphoma |
|
|
| Active, not recruiting | N/A | 1000 | RoW | No Intervention | Takeda | Lymphoma | 06/26 | 06/26 | | |
| Fan, Junqiang |
| No trials found |
